For medtech company Clinical Laserthermia System (CLS), 2021 was a year of strengthening both its organisation and its financial position. The company recruited new, experienced team members and carried out an oversubscribed rights issue ensuring a solid base for the future. CLS also demonstrated its resilience as it successfully navigated the process of finding new suppliers of sterilisation services. BioStock spoke to acting CEO Dan J. Mogren about 2021 and what we can expect from 2022.

Read the interview with CLS’ acting CEO Dan J. Mogren at biostock.se:

https://www.biostock.se/en/2022/01/cls-enters-2022-raring-to-go/